Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-26
1997-04-01
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514382, 514396, 514397, 548253, 5483151, 5483154, 5483345, C07D40310, C07D25704, A61K 3141, A61K 31415
Patent
active
056165994
ABSTRACT:
Compounds of the following formula (I) or the formula (I).sub.p : ##STR1## wherein R.sup.1 is alkyl or alkenyl; R.sup.2 and R.sup.3 are hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, aryl, or aryl fused to cycloalkyl; R.sup.4 is hydrogen, alkyl, alkanoyl, alkenoyl, arylcarbonyl, alkoxycarbonyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothienyl, tetrahydrofuryl, a group of formula --SiR.sup.a R.sup.b R.sup.c, in which R.sup.a, R.sup.b and R.sup.c are alkyl or aryl, alkoxymethyl, (alkoxyalkoxy)methyl, haloalkoxymethyl, aralkyl, aryl or alkanoyloxymethoxycarbonyl; R.sup.5 is carboxy or --CONR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 hydrogens or alkyl, or R.sup.8 and R.sup.9 together form alkylene; R.sup.6 is hydrogen, alkyl, alkoxy or halogen; R.sup.7 is carboxy or tetrazol-5-yl; R.sub.p.sup.1 is hydrogen, alkyl, cycloalkyl or alkanoyl; R.sub.p.sup.2 is a single bond, alkylene or alkylidene; R.sub.p.sup.3 and R.sub.p.sup.4 are each hydrogen or alkyl; R.sub.p.sup.6 is carboxy or tetrazol-5-yl; and X.sub.p is oxygen or sulfur; and pharmaceutically acceptable salts and esters thereof. The compounds are AII receptor antagonists and thus have hypotensive activity and can be used for the treatment and prophylaxis of hypertension. The compounds may be prepared by reacting a biphenylmethyl compound with an imidazole compound.
REFERENCES:
patent: 4226878 (1980-12-01), Iizuka et al.
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4342693 (1982-08-01), Sakamoto et al.
patent: 4355040 (1992-10-01), Furukawa et al.
patent: 4555516 (1985-11-01), Cross et al.
patent: 4812462 (1989-03-01), Blankley et al.
patent: 4816463 (1989-03-01), Blankley et al.
patent: 4820843 (1989-04-01), Aldrich et al.
patent: 4870186 (1989-09-01), Aldrich et al.
patent: 4874867 (1989-10-01), Aldrich et al.
patent: 4880804 (1989-11-01), Carini et al.
patent: 4916129 (1990-04-01), Carini et al.
patent: 5015651 (1991-05-01), Carini et al.
patent: 5039814 (1991-08-01), Shuman et al.
patent: 5043349 (1991-08-01), Carini et al.
patent: 5064825 (1991-11-01), Chakravarty et al.
patent: 5081127 (1992-01-01), Carini et al.
patent: 5089626 (1992-02-01), King
patent: 5093346 (1992-03-01), Carini et al.
patent: 5126342 (1992-06-01), Chakaravarty et al.
patent: 5128355 (1992-07-01), Carini et al.
patent: 5137902 (1992-08-01), Carini et al.
patent: 5138069 (1992-08-01), Carini et al.
patent: 5140037 (1992-08-01), Chiu et al.
patent: 5153197 (1992-10-01), Carini et al.
patent: 5155118 (1992-10-01), Carini et al.
patent: 5171748 (1992-12-01), Roberts et al.
patent: 5177097 (1993-01-01), Poss
patent: 5189048 (1993-02-01), Carini et al.
patent: 5210079 (1993-05-01), Carini et al.
patent: 5219856 (1993-06-01), Olson
patent: 5225414 (1993-07-01), Henning et al.
patent: 5236928 (1993-08-01), Chakravarty et al.
patent: 5236943 (1993-08-01), Heitsch et al.
patent: 5252753 (1993-11-01), Russell et al.
patent: 5254546 (1993-10-01), Ardecky et al.
patent: 5260322 (1993-11-01), Nakasima et al.
patent: 5266583 (1993-11-01), Ohtawa
patent: 5294716 (1994-03-01), Thomas et al.
patent: 5310928 (1994-05-01), Lo et al.
patent: 5310929 (1994-05-01), Ardecky et al.
patent: 5312828 (1994-05-01), Finkelstein et al.
patent: 5354867 (1994-10-01), Carini et al.
J. Duncia et al, "The Discovery of DUP-753 a Potent, Orally Active Nonpeptide Angiotensin II Receptor Antagonist": Medical Research Reviews, 12, 149-191 (1992).
A. Johnson et al, "Nonpeptide Angiotensin II Receptor Antagonists", Drug News & Perspectives (D N & P), 3, 337-351 (1990).
J. Hodges et al, "Angiotensin II Receptor Binding Inhibitors", Drugs of the Future, 17, 575-593 (1992).
P. Buhlmayer, "Angiotensin-II Antagonists: Patent Activity Since the Discovery of DUP-753", Current Opinion in Therapeutic Patents, 2, 1693-1718 (1992).
Wong et al, "Nonpeptide Angiotensin II Receptor Antagonists, XI, Pharmacology of EXP 3174: An Active Metabolite of DuP 753, An Orally Active Antihypertensive Agent", (1990), 211-217, 255, The Journal of Pharmacology and Experimental Therapeutics.
Carini et al., "Nonpeptide Angiotensin II Receptor Antagonists: The Discovery of a Series of N-(Biphenylylmethyl) Imidazoles as a Potent, Orally Active Antihypertensives", (1991), 2525-2547, 34, J. Med. Chem.
Merck Index, 11th Edition, p. 855, No.5319, Lenampicillin (1989).
Chem. Abs. 109:73432w of USP 4,812,462 (1988).
Chem. Abs. 114:164233b of EP 399732 (1991).
Chem. Abs. 114:228914j of EP 400835 (1991).
Amemiya Yoshiya
Fujimoto Koichi
Kanazaki Takuro
Koike Hiroyuki
Sada Toshio
Sankyo Company Limited
Springer David B.
LandOfFree
Angiotensin II antagosist 1-biphenylmethylimidazole compounds an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiotensin II antagosist 1-biphenylmethylimidazole compounds an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin II antagosist 1-biphenylmethylimidazole compounds an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-539309